评价艾司洛尔治疗感染性休克患者的疗效和安全性：系统评价和荟萃分析方案。
Evaluation of efficacy and safety of esmolol in treating patients with septic shock: A protocol for systematic review and meta-analysis.
机构信息
Department of Critical Medicine, Taizhou People's Hospital, Taizhou, Jiangsu Province, China.
出版信息
Medicine (Baltimore). 2022 Apr 1;101(13):e29124. doi: 10.1097/MD.0000000000029124.
BACKGROUND
In septic shock cases, tachycardia and a hyperdynamic hemodynamic profile are characteristics of the condition. It has been reported that using beta antagonist esmolol constitutes a form of treatment to reduce heart rate to improve diastolic filling time and elevate cardiac output, which reduces vasopressor support. Still, there are controversial results. Therefore, in this study, the primary objective is to perform a meta-analysis by systematically evaluating the efficiency and security of using esmolol to treat septic shocks.
METHODS
A systematic literature search for relevant randomized controlled trials that report evaluations on the efficiency and safety of using esmolol to treat septic shock patients from their inception to February 2022 will be conducted in three databases containing publications in Chinese language (WanFang, Chinese BioMedical Literature Database, and China National Knowledge Infrastructure) and four databases containing English language publications (Cochrane Library, PubMed, Web of Science, and EMBASE). The screening of the relevant studies will be performed by a pair of authors independently, and the screening involves examining the title, abstract and full-text stages, data extraction, and bias risk assessment. The results are summarized through the fixed-effects and random-effects models, the respective models will be utilized for data pooling according to the heterogeneity of studies that will be included. Moreover, publication bias is assessed if more than ten studies are considered.
RESULTS
The results are a high-quality synthesis of the most recent evidence for esmolol usage in septic shock treatment.
CONCLUSION
Up-to-date evidence will be provided through the results of this systematic review related to assessing the efficacy and safeness of esmolol usage in treating septic shock.
ETHICS AND DISSEMINATION
Ethical permissions are not required as prepublished data are used.
OSF REGISTRATION NUMBER
DOI 10.17605/OSF.IO/SKEZ7.
背景
在感染性休克病例中，心动过速和高动力性血液动力学特征是该病症的特点。据报道，使用β受体阻滞剂艾司洛尔可作为一种治疗方法，以降低心率，改善舒张充盈时间并提高心输出量，从而减少血管加压支持。然而，结果仍存在争议。因此，在这项研究中，主要目的是通过系统评估使用艾司洛尔治疗感染性休克的疗效和安全性来进行荟萃分析。
方法
从研究开始到 2022 年 2 月，我们将在三个包含中文出版物的数据库（万方、中国生物医学文献数据库和中国国家知识基础设施）和四个包含英文出版物的数据库（Cochrane 图书馆、PubMed、Web of Science 和 EMBASE）中，对报告评估使用艾司洛尔治疗感染性休克患者的效率和安全性的相关随机对照试验进行系统文献检索。由两名作者独立筛选相关研究，筛选包括检查标题、摘要和全文阶段、数据提取和偏倚风险评估。结果通过固定效应和随机效应模型进行总结，将根据纳入研究的异质性，分别使用各自的模型进行数据合并。如果考虑到超过十项研究，则评估发表偏倚。
结果
这是感染性休克治疗中使用艾司洛尔的最新证据的高质量综合。
结论
本系统评价的结果将提供有关评估艾司洛尔在治疗感染性休克中的疗效和安全性的最新证据。
伦理与传播
由于使用了预发表的数据，因此不需要伦理许可。
OSF 注册号：DOI 10.17605/OSF.IO/SKEZ7。
Zotero 插件